Thromboembolic events are the second leading cause of death in cancer patients. Hemostatic disorders ranging from asymptomatic laboratory changes to catastrophic disseminated intravascular coagulation (DIC) could be associated with solid tumors. Thrombotic events may preecede the diagnosis of malignancy; hence, patients with unexplained recurrent venous and/or arterial thrombosis should be investigated for an occult malignancy (1) .
Routine laboratory tests do not predict hematologic complications in advance. More sensitive tests for the detection of subclinical activation of fibrinolysis and compensated DIC have been developed but none are proven to be correlated with clinical events (2) .
In this study, we used a new method to assess global fibrinolytic capacity of both intrinsic and extrinsic pathways in patients with colorectal cancer. The test has the ability of detecting subclinical activation of fibrinolysis.
METHODS
Twenty patients with biopsy-proven colorectal cancer and 20 age-and sex-matched healthy control subjects were enrolled into the study. Twelve patients had colonic carcinoma and the other eight patients had rectal cancer. The patients had not received any therapeutic intervention before the study. All patients were eligible for therapeutic colorectal resection. Nonsteroidal anti-inflammatory drugs and any other medication that might interfere with coagulation tests were discontinued 10 days before the study.
Venous blood samples were drawn before and 3 weeks after the surgery. Blood samples for coagulation tests were drawn into tubes containing 3 One patient in whom deep venous thrombosis developed in postoperative period was examined for the hereditary thrombophilic disorders (activated protein C resistance, hyperhomocysteinemia, protein C, protein S, and antithrombin III deficiencies); no abnormality was found.
The results are shown in Table 1 . (2, (6) (7) (8) (9) (10) (11) (12) (13) . Thrombocytosis and increased plasma fibrinogen levels are the most common abnormalities (2, 6, (13) (14) (15) . The other commonly observed laboratory changes are prolongation or shortening of prothrombin and partial thromboplastin times; and increase or decrease in fibrinogen, and factors V, VIII, IX, XI, and XII (2, 13, 14) . In our postoperative patient group, fibrinogen levels were significantly increased, which may reflect acute phase reaction to surgical trauma.
New biochemical markers and laboratory tests were developed to detect subclinical activation of coagulation or fibrinolysis. These tests generally indicate various forms of hemostatic imbalance including subclinical activation of coagulation, consumption or increased synthesis of coagulation factors, and compensated fibrinolysis in cancer patients (2, 13, 15) . Fibrinopeptide A (FPA), a degradation product of fibrinogen by thrombin, for example, is increased in disseminated solid malignancies or acute leukemias (16) . FPA levels were found to be correlated with tumor burden; increasing levels can be the first sign of relapsing disease in acute leukemias. Although many new coagulation tests bring promising results in early detection of hemostatic disorders, no one is proven to be correlated with clinical events (2) .
Interacting and counteracting mechanisms of coagulation and fibrinolysis bring out different states of hemostatic imbalance in accord to type and extend of tumor, treatment modalities, and accompanying complications. Catabolism of fibrinogen and platelets is increased in disseminated malignancies as evidenced by increased levels of fibrin degredation products, D-dimer, prothrombin fragment 1 + 2, fibrinopeptide A and B, cryoglobulins, fibrin monomer, platelet factor 4, beta thromboglobulin, fibronectin, and antithrombin (2, (12) (13) (14) (15) (16) (17) (18) (19) 
